What a Peptide Actually Is

The bond

An amino acid is a small organic molecule with two functional groups on opposite ends: an amine group at one end and a carboxyl group at the other, with a variable side chain hanging off the middle. That side chain is the only thing distinguishing one amino acid from another, and there are twenty of them used in ordinary human biology.

Join the carboxyl end of one amino acid to the amine end of the next, release a molecule of water, and you have made a peptide bond. Do it repeatedly and you get a chain. The chain has direction: the end with a free amine group is the N-terminus, conventionally written on the left; the end with a free carboxyl group is the C-terminus, written on the right. When you see a sequence written out, as in His-Ala-Glu-Gly-Thr..., you are reading it N to C.

That is the entire structural definition. A peptide is a chain of amino acids linked by peptide bonds. Everything else is a question of length and decoration.

Where the line sits

The distinction between a peptide and a protein is conventional rather than fundamental, and you should know that so you are not misled by anyone who insists otherwise. The working convention:

The boundary at fifty is arbitrary. Insulin is fifty-one residues across two chains and is called a protein by some sources and a peptide hormone by others; both are defensible. What matters is not the label but the practical consequence of size, which is real and which you will meet constantly.

What a peptide is not

Three contrasts do most of the useful work.

Not a small molecule

Aspirin, caffeine, metformin, and most of what a pharmacy dispenses are small molecules: rigid, low molecular weight, chemically stable, and, crucially, able to survive the stomach. Peptides generally cannot. The digestive tract is an apparatus specifically evolved to disassemble peptide bonds, because dietary protein is exactly that. Swallow a peptide and you have, in most cases, eaten a very expensive and unusually pure snack.

This is the single reason injection dominates the field. It is not a preference or a subculture; it is a route-of-administration problem imposed by the molecule's own chemistry. Where oral peptide drugs do exist, they exist because someone solved that problem deliberately and at enormous expense. Oral semaglutide, for instance, is co-formulated with an absorption enhancer that transiently raises local gastric pH and shields the peptide long enough for a fraction of the dose to cross. The bioavailability is still around one per cent.¹

Not a steroid

Anabolic steroids are lipid-based small molecules that pass through the cell membrane and bind receptors inside the cell, typically altering gene transcription directly. Peptides are water-soluble and generally cannot cross the membrane at all. They bind receptors on the cell surface and trigger a relay inside. Different chemistry, different pharmacology, different risk profile, different everything. The two get discussed in the same forums, which produces a steady supply of category errors.

Not a supplement

This is a legal point rather than a chemical one, and it gets a full treatment in Module 03. In brief: peptides are, in most jurisdictions, not eligible to be sold as dietary supplements, and a product marketed as one is telling you something about its seller.

Decoration: why so few compounds are the native molecule

Native signalling peptides tend to be destroyed within minutes of entering circulation. Native GLP-1 has a half-life of roughly two minutes, because an enzyme called DPP-4 clips it almost immediately. A drug that requires re-dosing every two minutes is not a drug. So nearly every peptide you will encounter is a modified version of something the body makes, engineered to survive longer. The common modifications:

• Amino acid substitution. Swap the residue the degrading enzyme recognises. Change one position and DPP-4 no longer cleaves it.
• D-amino acid substitution. Every amino acid in human biology is the L-enantiomer, the left-handed mirror image. Human peptidases recognise L. Substitute a D residue and the enzyme cannot get purchase.
• Fatty acid acylation. Attach a lipid chain that binds circulating albumin. The peptide is then carried around bound to a large protein, sheltered from filtration and degradation, released slowly. This is how semaglutide gets from two minutes to roughly a week.
• PEGylation. Attach polyethylene glycol to increase effective size and slow renal clearance.
• Cyclisation. Join the ends into a ring, removing the exposed termini that exopeptidases attack.
• Truncation. Keep only the fragment that does the binding and discard the rest. Several familiar compounds are fragments of larger native proteins.

When a vendor lists a compound as an "analogue", "fragment", or "mimetic", these are the operations being referred to. An analogue is the native molecule with substitutions. A fragment is a piece of it. A mimetic is a different molecule entirely that happens to fit the same receptor.

A modified peptide is not the native hormone. It is a molecule designed to be mistaken for one, for longer.

Reading the name

Pharmaceutical naming is systematic, and once you know the system you can extract real information from a name before you read anything else about it.

A compound with a code name rather than a stem name, such as the letter-number designations BPC-157 or MOTS-c, has generally not been through a naming process, which itself tells you something about how far through development it is. That is not a verdict on the compound. It is a data point about how much is known.

What you should be able to do now

• State what a peptide bond is and which direction a sequence is read.
• Explain why oral administration is generally not viable, without invoking anything but chemistry.
• Distinguish an analogue from a fragment from a mimetic.
• Look at a compound name and infer whether it has been through formal drug development.

Module 02 takes the next step: what happens after the molecule arrives.